Discontinued — last reported Q1 '18
RB Global Allowance for Doubtful Accounts Receivable (Current) increased by 5.8% to $9.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.7%, from $7.30M to $9.10M. Over 3 years (FY 2022 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 37.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q4 '22 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.30M | $4.90M | $6.40M | $8.40M | $8.70M | $8.40M | $7.20M | $7.30M | $7.00M | $5.50M | $8.60M | $9.10M |
| QoQ Change | — | +48.5% | +30.6% | +31.3% | +3.6% | -3.4% | -14.3% | +1.4% | -4.1% | -21.4% | +56.4% | +5.8% |
| YoY Change | — | — | +93.9% | — | — | +71.4% | +12.5% | -13.1% | -19.5% | -34.5% | +19.4% | +24.7% |